# Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19

> **NCT04751682** · PHASE1 · COMPLETED · sponsor: **Bharat Biotech International Limited** · enrollment: 175 (actual)

## Conditions studied

- SARS-CoV Infection

## Interventions

- **BIOLOGICAL:** BBV154 Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04751682
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2021-06-25
- **Final completion:** 2021-11-30
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04751682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04751682, "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04751682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*